SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma zooms despite reporting 16% fall in Q2 consolidated net profit

05 Nov 2024 Evaluate

Gland Pharma is currently trading at Rs. 1814.85, up by 205.00 points or 12.73% from its previous closing of Rs. 1609.85 on the BSE.

The scrip opened at Rs. 1600.00 and has touched a high and low of Rs. 1824.20 and Rs. 1600.00 respectively. So far 60279 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2220.95 on 06-Aug-2024 and a 52 week low of Rs. 1503.70 on 06-Nov-2023.

Last one week high and low of the scrip stood at Rs. 1824.20 and Rs. 1600.00 respectively. The current market cap of the company is Rs. 29342.28 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 39.84% and 8.32% respectively.

Gland Pharma has reported 9.39% rise in its net profit at Rs 281.71 crore for second quarter ended September 30, 2024 (Q2FY25) as compared to Rs 257.53 crore for the same quarter in the previous year. Total income of the company increased by 6.56% at Rs 1,120.79 crore for Q2FY25 as compared to Rs 1,051.78 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 15.74% fall in net profit at Rs 163.53 crore for Q2FY25 as compared to Rs 194.08 crore for the same quarter in the previous year. However, total income of the company increased by 2.73% at Rs 1,465.49 crore for Q2FY25 as compared to Rs 1,426.58 crore for the corresponding quarter previous year.

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×